Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397877 | 0.80 | ADRB2 (0.36) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL3835007 | 0.76 | TSHR (0.34) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL14021471 | 0.73 | ADRB2 (0.31) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL3634742 | 0.71 | ADRB2 (0.33) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL12314357 | 0.70 | ALDH1A1 (0.32) | ADRB2ADRB1ADRB3ALDH1A1CA1 | |
| SCHEMBL223099 | 0.69 | ADRB2 (0.45) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL9719492 | 0.69 | ADRB2 (0.45) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| Trimethylammonium SCHEMBL28169641 | 0.69 | ADRB2 (0.39) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL7639823 | 0.67 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL11594064 | 0.67 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| EP-3716982-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2714092-B1 | IMMUNOCONJUGATES, COMPOSITIONS CONTAINING THEM, AND METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20160046576-A1 | NOVEL PYRROLE DERIVATIVES | UNIV LEICESTER (GB) | 2016-02-18 | — | — | US | disclosed |
| US-9221756-B2 | Pyrrole derivatives | UNIVERSITY OF LEICESTER (GB) | 2015-12-29 | — | — | US | disclosed |
| US-20140364585-A1 | IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-11 | — | — | US | disclosed |
| US-20140309193-A1 | NOVEL PYRROLE DERIVATIVES | UNIVERSITY OF LEICESTER (GB) | 2014-10-16 | — | — | US | disclosed |
| WO-2013083975-A2 | NOVEL PYRROLE DERIVATIVES | UNIVERSITY OF LEICESTER (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013012416-A1 | PROCESS FOR PREPARING PHOSPHORYLATED AMINO ACIDS | CEPHALON, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012846-A1 | PROCESS FOR PREPARING PHOSPHORYLATED AMINO ACIDS | CEPHALON, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2012162482-A1 | IMMUNOCONJUGATES, COMPOSITIONS CONTAINING THEM, AND METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| EP-2102201-A2 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008073311-A2 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1742911-A1 | 3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102997-A1 | 3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| EP-0468998-A1 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990012804-A2 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364585-A1 | IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE | TOP1, TOP2B, OGG1 | ADRB2 4658/4885ADRB1 4384/4885ADRB3 4403/4885 |
| US-20160046576-A1 | NOVEL PYRROLE DERIVATIVES | PYCR1, ARG1, PNISR | ADRB2 2709/4885ADRB1 1773/4885ADRB3 2641/4885 |
| US-20140309193-A1 | NOVEL PYRROLE DERIVATIVES | PYCR1, ARG1, PNISR | ADRB2 2709/4885ADRB1 1773/4885ADRB3 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.